This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.
Gilead Sciences is a top pharmaceutical company based in California, USA
Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen
Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced
Sorry, your search returned no results.
Ono Pharmaceutical and Gilead Sciences have entered into an exclusive license agreement for the development and commercialization of ONO-4059
Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.
Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate).
Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.
Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.